Prednisolone is a synthetic corticosteroid.
Prednisolone acetate or sodium phosphate is applied topically to the eye. Care should be taken to avoid contamination of the tip of the ointment tube or dropper when the drug is used ophthalmically.
Potency of some sodium phosphate preparations is expressed in terms of prednisolone phosphate.
For use in the eye, 1 or 2 drops of prednisolone acetate ophthalmic suspension or prednisolone sodium phosphate ophthalmic solution may be instilled into the conjunctival sac every hour during the day and every 2 hours during the night for initial therapy in severe cases. In mild or moderate inflammation or when a favorable response is attained in severe cases, dosage may be reduced to 1 or 2 drops every 3-12 hours.
Alternatively, prednisolone sodium phosphate ophthalmic ointment may be instilled into the conjunctival sac 3 or 4 times daily initially, and once or twice daily thereafter. The ointment also may be used at night in conjunction with daytime use of a suspension or solution to reduce the frequent applications required with the liquid dosage forms.
The lowest effective concentration should be used and, if improvement does not occur within several days, the drug should be discontinued and other therapy begun. The duration of treatment depends on the type and severity of the disease and may range from a few days to several weeks; long-term therapy should be avoided. When the drug is discontinued, dosage should be gradually tapered to avoid exacerbation of the disease.
Prednisolone is a synthetic glucocorticoid. Prednisolone acetate occurs as a white to practically white, odorless, crystalline powder and is practically insoluble in water and slightly soluble in alcohol. The sodium phosphate ester of prednisolone occurs as slightly hygroscopic, white or slightly yellow, friable granules or powder which is odorless or has a slight odor and is freely soluble in water and slightly soluble in alcohol. The pH of prednisolone acetate ophthalmic suspension is 5-6. The pH of prednisolone sodium phosphate ophthalmic solution is 6.2-8.2.
Prednisolone sodium phosphate ophthalmic solution should be stored in tight, light-resistant containers and should be protected from freezing.
Additional Information
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer's labeling should be consulted for more detailed information. The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Bulk | Powder | |||
Ophthalmic | Suspension | 0.12% | Pred Mild® | Allergan |
1%* | Econopred® Plus | Alcon | ||
Pred Forte® | Allergan | |||
Prednisolone Acetate Ophthalmic Suspension |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | Gentamicin Sulfate 0.3% (of gentamicin) and Prednisolone Acetate 0.6% | Pred-G® | Allergan |
Suspension | Gentamicin Sulfate 0.3% (of gentamicin) and Prednisolone Acetate 1% | Pred-G® (viscous) | Allergan |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Suspension | Neomycin Sulfate 0.35% (of neomycin), Polymyxin B Sulfate 10,000 units (of polymyxin B) per mL, and Prednisolone Acetate 0.5% | Poly-Pred® (viscous) | Allergan |
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Ointment | 10% Sulfacetamide Sodium and Prednisolone Acetate 0.2% | Blephamide® | Allergan |
Suspension | 10% Sulfacetamide Sodium and Prednisolone Acetate 0.2%* | Blephamide® (viscous) | Allergan |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Solution | 0.125% (0.11% of prednisolone phosphate)* | Inflamase® Mild | Novartis |
Prednisolone Sodium Phosphate Ophthalmic Solution | ||||
1% (0.9% of prednisolone phosphate)* | AK-Pred® | Akorn | ||
Inflamase® Forte | Novartis | |||
Prednisolone Sodium Phosphate Ophthalmic Solution |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Routes | Dosage Forms | Strengths | Brand Names | Manufacturer |
---|---|---|---|---|
Ophthalmic | Solution | 0.25% (0.23% of prednisolone phosphate) with Sulfacetamide Sodium 10%* | Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Solution | Bausch & Lomb |
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name